Yager

Investor

[Investing.com @Investingcom]

⚠️BREAKING:

*WALL STREET OPENS HIGHER ON RUSSIA RELIEF; NASDAQ JUMPS 2%

🇺🇲🇺🇲

[Athersys Inc @athersys]

Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer https://t.co/Ho4MPPL8re

[Yager @TheOnlyYager]

$MOR

[Incyte @Incyte]

#News: Data from the RE-MIND2 study in relapsed or refractory diffuse large B-cell lymphoma is being presented at the @ASH_hematology. #ASH21

[Athersys Inc @athersys]

Our goals at #Athersys align with one common mission - to deliver our product to patients in need. Through advancing our #clinicaltrials, we look forward to the potential of having #MultiStem be commercially available. Read more about our product here: https://t.co/0cipJLMamo

[Athersys Inc @athersys]

Dr. Eric Jenkins, Senior Medical Director and Head of Clinical Operations at Athersys, discusses the Phase 1/2 MUST-ARDS clinical trial and the importance of the study's recent publication in the peer-reviewed journal, Intensive Care Medicine. https://t.co/FWBUB2P320

[Yager @TheOnlyYager]

$CTIC

[Athersys Inc @athersys]

ICYMI: Dr. Robert (Willie) Mays @SayHay66 presented the Athersys corporate presentation at @alliancerm’s #CGMesa21. Watch the presentation below!

https://t.co/lGmz7FVxzB

[Incyte @Incyte]

We’re pleased to present to the #oncology community, health care professionals & industry partners at the @SITCancer congress. Join us at #SITC21 to learn more about our data presentations. https://t.co/CSzfcEIzDF

[Athersys Inc @athersys]

Preparing for the commercialization of a completely new and innovative therapy requires careful planning. Meet SIFU, our Secure Integrated Freezer Unit that we have been developing to store and dispense #MultiStem vials in pharmacies worldwide.

#ATHXFacts

[Yager @TheOnlyYager]

$INCY

[Dr. Tadahisa "Hardy" Kagimoto, MD 鍵本 忠尚 @HardyTSKagimoto]

ARDS is such a devastating disease. We are moving forward to cure those who are on the verge of death. Let us cure this disease! Please join us, help us to make it happen! https://t.co/48EJFmIazk

[Incyte @Incyte]

Incyte's recent recognition as one of America’s Most Loved Workplaces of 2021 by @Newsweek is driven by our belief in fostering a company culture that is built on collaboration & innovation. Hear more from some of our employees. https://t.co/XvTp4x3SO5

[Yager @TheOnlyYager]

$EYEN

[Yager @TheOnlyYager]

$MNOV

[Yager @TheOnlyYager]

$RVNC

[Yager @TheOnlyYager]

Buying $ALLO

[Yager @TheOnlyYager]

@BillyBoorn The 30 days may start ticking after the company reviews the concern and updates the FDA...

[Yager @TheOnlyYager]

$PTGX current FDA Hold - should be addressed by 10/17.

[Yager @TheOnlyYager]

@BillyBoorn No, the date is not a hard date. 10/17 is just 30 days out from the hold. My understanding is FDA generally follows up with addressing the hold within 30 days so thinking we should hear something by 10/17. Let me know if you read it any differently...

https://t.co/bL30qiUkbo

[Yager @TheOnlyYager]

$OYST Catalyst on 10/17.